These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 29961897)

  • 1. Targeting the PI3K/Akt/mTOR signaling pathway by pterostilbene attenuates mantle cell lymphoma progression.
    Yu D; Zhang Y; Chen G; Xie Y; Xu Z; Chang S; Hu L; Li B; Bu W; Wang Y; Xiao W; Sun X; Chang G; Gao L; Qiang S; Wu X; Zhu W; Shi J
    Acta Biochim Biophys Sin (Shanghai); 2018 Aug; 50(8):782-792. PubMed ID: 29961897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effects of the phosphoinostitide-3'-kinase delta inhibitor, CAL-101, in combination with Bortezomib on mantle lymophma cells and exploration of its related mechanism].
    Qu F; Xia B; Li X; Guo S; Zhang L; Tian C; Yu Y; Zhang Y
    Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):412-7. PubMed ID: 26463142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Counteracting autophagy overcomes resistance to everolimus in mantle cell lymphoma.
    Rosich L; Xargay-Torrent S; López-Guerra M; Campo E; Colomer D; Roué G
    Clin Cancer Res; 2012 Oct; 18(19):5278-89. PubMed ID: 22879389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.
    Kim A; Seong KM; Kang HJ; Park S; Lee SS
    Oncotarget; 2015 Nov; 6(35):38225-38. PubMed ID: 26517678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma.
    Müller A; Zang C; Chumduri C; Dörken B; Daniel PT; Scholz CW
    Int J Cancer; 2013 Oct; 133(8):1813-24. PubMed ID: 23580240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual inhibition of CDK4/Rb and PI3K/AKT/mTOR pathways by ON123300 induces synthetic lethality in mantle cell lymphomas.
    Divakar SK; Ramana Reddy MV; Cosenza SC; Baker SJ; Perumal D; Antonelli AC; Brody J; Akula B; Parekh S; Reddy EP
    Leukemia; 2016 Jan; 30(1):86-93. PubMed ID: 26174628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma.
    Peponi E; Drakos E; Reyes G; Leventaki V; Rassidakis GZ; Medeiros LJ
    Am J Pathol; 2006 Dec; 169(6):2171-80. PubMed ID: 17148679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PF-04691502, a dual PI3K/mTOR inhibitor has potent pre-clinical activity by inducing apoptosis and G1 cell cycle arrest in aggressive B-cell non-Hodgkin lymphomas.
    Chen D; Mao C; Zhou Y; Su Y; Liu S; Qi WQ
    Int J Oncol; 2016 Jan; 48(1):253-60. PubMed ID: 26549638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arsenic trioxide rewires mantle cell lymphoma response to bortezomib.
    Zhao LL; Liu YF; Peng LJ; Fei AM; Cui W; Miao SC; Hermine O; Gressin R; Khochbin S; Chen SJ; Wang J; Mi JQ
    Cancer Med; 2015 Nov; 4(11):1754-66. PubMed ID: 26310857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pterostilbene Inhibits Human Multiple Myeloma Cells via ERK1/2 and JNK Pathway In Vitro and In Vivo.
    Xie B; Xu Z; Hu L; Chen G; Wei R; Yang G; Li B; Chang G; Sun X; Wu H; Zhang Y; Dai B; Tao Y; Shi J; Zhu W
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27869675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma.
    Li J; Wang X; Xie Y; Ying Z; Liu W; Ping L; Zhang C; Pan Z; Ding N; Song Y; Zhu J
    Int J Cancer; 2018 Jan; 142(1):202-213. PubMed ID: 28905990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pterostilbene (3',5'-dimethoxy-resveratrol) exerts potent antitumor effects in HeLa human cervical cancer cells via disruption of mitochondrial membrane potential, apoptosis induction and targeting m-TOR/PI3K/Akt signalling pathway.
    Hong Bin W; Da LH; Xue Y; Jing B
    J BUON; 2018; 23(5):1384-1389. PubMed ID: 30570862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms.
    Nguyen T; Parker R; Zhang Y; Hawkins E; Kmieciak M; Craun W; Grant S
    BMC Cancer; 2018 Nov; 18(1):1129. PubMed ID: 30445933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
    Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells.
    Kim A; Park S; Lee JE; Jang WS; Lee SJ; Kang HJ; Lee SS
    Leuk Res; 2012 Jul; 36(7):912-20. PubMed ID: 22560334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 20(S)-Protopanaxadiol-Induced Apoptosis in MCF-7 Breast Cancer Cell Line through the Inhibition of PI3K/AKT/mTOR Signaling Pathway.
    Zhang H; Xu HL; Wang YC; Lu ZY; Yu XF; Sui DY
    Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29614812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 8-Aminoadenosine inhibits Akt/mTOR and Erk signaling in mantle cell lymphoma.
    Dennison JB; Shanmugam M; Ayres ML; Qian J; Krett NL; Medeiros LJ; Neelapu SS; Rosen ST; Gandhi V
    Blood; 2010 Dec; 116(25):5622-30. PubMed ID: 20844237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications.
    Pham LV; Tamayo AT; Li C; Bornmann W; Priebe W; Ford RJ
    Mol Cancer Ther; 2010 Jul; 9(7):2026-36. PubMed ID: 20606045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The miRNA-17∼92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation.
    Rao E; Jiang C; Ji M; Huang X; Iqbal J; Lenz G; Wright G; Staudt LM; Zhao Y; McKeithan TW; Chan WC; Fu K
    Leukemia; 2012 May; 26(5):1064-72. PubMed ID: 22116552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel treatment for mantle cell lymphoma including therapy-resistant tumor by NF-κB and mTOR dual-targeting approach.
    Chaturvedi NK; Rajule RN; Shukla A; Radhakrishnan P; Todd GL; Natarajan A; Vose JM; Joshi SS
    Mol Cancer Ther; 2013 Oct; 12(10):2006-17. PubMed ID: 23963361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.